Abstract

The ability of HDL to support macrophage cholesterol efflux is an integral part of its atheroprotective action. Augmenting this ability, especially when HDL cholesterol efflux capacity from macrophages is poor, represents a promising therapeutic strategy. One approach to enhancing macrophage cholesterol efflux is infusing blood with HDL mimics. Previously, we reported the synthesis of a functional mimic of HDL (fmHDL) that consists of a gold nanoparticle template, a phospholipid bilayer, and apo A-I. In this work, we characterize the ability of fmHDL to support the well-established pathways of cellular cholesterol efflux from model cell lines and primary macrophages. fmHDL received cell cholesterol by unmediated (aqueous) and ABCG1- and scavenger receptor class B type I (SR-BI)-mediated diffusion. Furthermore, the fmHDL holoparticle accepted cholesterol and phospholipid by the ABCA1 pathway. These results demonstrate that fmHDL supports all the cholesterol efflux pathways available to native HDL and thus, represents a promising infusible therapeutic for enhancing macrophage cholesterol efflux. fmHDL accepts cholesterol from cells by all known pathways of cholesterol efflux: unmediated, ABCG1- and SR-BI-mediated diffusion, and through ABCA1.

Highlights

  • The ability of HDL to support macrophage cholesterol efflux is an integral part of its atheroprotective action

  • The results show that functional mimic of HDL (fmHDL) accepts cellular cholesterol by unmediated and ABCG1- and SR-BIfacilitated diffusion, and by the critically important antiatherogenic ABCA1 pathway and may provide a means to increase HDL-C efflux capacity (HDL-CEC) and alleviate coronary artery disease (CAD)

  • In our working model of the fmHDL nanostructure, an Au gold nanoparticle (NP) core is enveloped in a bilayer of either phospholipid and apolipoprotein, as in fmHDL and fmHDL, or phospholipid alone, as in fmHDL (Fig. 1)

Read more

Summary

Introduction

The ability of HDL to support macrophage cholesterol efflux is an integral part of its atheroprotective action. One approach to enhancing macrophage cholesterol efflux is infusing blood with HDL mimics. We characterize the ability of fmHDL to support the well-established pathways of cellular cholesterol efflux from model cell lines and primary macrophages. The fmHDL holoparticle accepted cholesterol and phospholipid by the ABCA1 pathway. These results demonstrate that fmHDL supports all the cholesterol efflux pathways available to native HDL and represents a promising infusible therapeutic for enhancing macrophage cholesterol efflux. FmHDL accepts cholesterol from cells by all known pathways of cholesterol efflux: unmediated, ABCG1- and SR-BI-mediated diffusion, and through ABCA1.—Luthi, A.

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.